Our top pick for
Building a portfolio
CareDx, Inc is a diagnostics & research business based in the US. CareDx shares (CDNA) are listed on the NASDAQ and all prices are listed in US Dollars. CareDx employs 456 staff and has a trailing 12-month revenue of around USD$192.2 million.
|52-week range||USD$20.6693 - USD$99.83|
|50-day moving average||USD$71.4734|
|200-day moving average||USD$65.732|
|Wall St. target price||USD$98|
|Dividend yield||USD$1.576 (2.2%)|
|Earnings per share (TTM)||USD$-0.971|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$192.2 million|
|Gross profit TTM||USD$80.1 million|
|Return on assets TTM||-5.41%|
|Return on equity TTM||-9.94%|
|Market capitalisation||USD$3.8 billion|
TTM: trailing 12 months
There are currently 5.2 million CareDx shares held short by investors – that's known as CareDx's "short interest". This figure is 10.5% up from 4.7 million last month.
There are a few different ways that this level of interest in shorting CareDx shares can be evaluated.
CareDx's "short interest ratio" (SIR) is the quantity of CareDx shares currently shorted divided by the average quantity of CareDx shares traded daily (recently around 999981.97674419). CareDx's SIR currently stands at 5.16. In other words for every 100,000 CareDx shares traded daily on the market, roughly 5160 shares are currently held short.
However CareDx's short interest can also be evaluated against the total number of CareDx shares, or, against the total number of tradable CareDx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CareDx's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 CareDx shares in existence, roughly 100 shares are currently held short) or 0.112% of the tradable shares (for every 100,000 tradable CareDx shares, roughly 112 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CareDx.
Find out more about how you can short CareDx stock.
We're not expecting CareDx to pay a dividend over the next 12 months.
Over the last 12 months, CareDx's shares have ranged in value from as little as $20.6693 up to $99.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CareDx's is 0.6387. This would suggest that CareDx's shares are less volatile than average (for this exchange).
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.